上海医药(02607)：硫酸艾沙康唑原料药上市申请获得批准

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of the active pharmaceutical ingredient Isavuconazole sulfate [1] Group 1 - Shanghai Pharmaceuticals Group Co., Ltd. has announced that its subsidiary, Shanghai Pharmaceuticals Kangli (Changzhou) Pharmaceutical Co., Ltd., has obtained the approval notice for the listing application of Isavuconazole sulfate [1] - The approval is indicated by the certificate number 2025YS01127, allowing the company to commence production of the drug [1]